An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
Positive QuantiFERON-CMV results increased after letermovir prophylaxis completion. Predictive utility of the QuantiFERON-CMV assay may be limited in the HCT setting.
Authors
- Ella Ariza‐Heredia (ORCID: https://orcid.org/0000-0003-4543-6177)
- Cyrus Badshah
- Sanjeet Dadwal (ORCID: https://orcid.org/0000-0002-1099-0568)
- Patrizia Chiusolo (ORCID: https://orcid.org/0000-0002-1355-1587)
- Eleni Tholouli
- Genovefa A. Papanicolaou (ORCID: https://orcid.org/0000-0002-2891-079X)
- Barbara Haber (ORCID: https://orcid.org/0000-0001-6315-5470)
- Natalya Broyde (ORCID: https://orcid.org/0009-0006-1512-2838)
- Michele I. Morris (ORCID: https://orcid.org/0000-0002-4479-8726)
- Chantal Gilbert (ORCID: https://orcid.org/0009-0000-7785-3229)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- Cornell University (US)
- Manchester Royal Infirmary (GB)
- Agostino Gemelli University Polyclinic (IT)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1093/cid/ciaf646
- Citations
- 1
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.35